Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female~* At least 18 years of age~* With a diagnosis of Clostridium Difficile-associated diarrhea (CDAD): first occurrence or first recurrence.~Key Exclusion Criteria:~* Concurrent life threatening condition.~* Immuno-compromised subjects, concomittant immuno-suppresive treatment.~* Concomitant antimicrobial treatment for CDAD.~* Any circumstances or conditions, which, in the opinion of the investigator, would affect full participation of the subject in the study or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cadazolid 250 mg (Type: EXPERIMENTAL): Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
- Cadazolid 500 mg (Type: EXPERIMENTAL): Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
- Cadazolid 1000 mg (Type: EXPERIMENTAL): Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
- Vancomycin 125 mg (Type: ACTIVE_COMPARATOR): Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).